Glenmark Pharma Launches Key Injection in US, Eyes $50.7M Market Share

• Glenmark Pharmaceuticals launched Potassium Phosphates Injection USP in the US market.
• Available in multiple dosage strengths: 15 mmol P / 22 mEq K per 5 mL, 45 mmol P / 66 mEq K per 15 mL, and 150 mmol P / 220 mEq K per 50 mL.
• The product is bioequivalent and therapeutically equivalent to Fresenius Kabi's reference listed drug.
• Distribution is set to begin in March 2026, targeting a market with annual sales of $50.7 million.
• Marc Kikuchi stated the launch expands Glenmark's institutional portfolio and commitment to affordable injectable medicines.